MISSISSAUGA, ON, June 19, 2015 /PRNewswire/ - Cipher
Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that
Shawn Patrick O'Brien, President and
Chief Executive Officer, will present at the 2015 JMP Securities
Life Sciences Conference in New
York on Tuesday, June 23,
2015. The presentation will take place at 9:30 AM ET and will be followed by a Q&A
session.
A live audio webcast of the presentation will be available by
accessing the Investor Relations section of the Company's
website at www.cipherpharma.com. The webcast replay will be
available approximately two hours after the presentation ends and
will be accessible for six months.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (NASDAQ:CPHR; TSX:CPH) is a rapidly
growing specialty pharmaceutical dermatology company with a
diversified portfolio of commercial-stage products that is on pace
to achieve its goal of becoming the most customer-centric
dermatology company in North
America. Cipher acquires best-in-class products and/or
potentially transformative compounds that fulfill high unmet
medical needs. Cipher's experienced management team has a proven
track of successfully managing the required clinical development
and regulatory approval processes and marketing products either
directly or through partners.
Cipher has completed six transactions in 2015, including the
acquisition of Innocutis and its seven branded dermatology
products, to build its U.S. commercial presence, expand its
Canadian dermatology franchise and broaden its pipeline. Its
products include a novel version of the acne medication
isotretinoin, which is marketed as Absorica® in the United States and Epuris® in Canada. Cipher is well-capitalized to drive
long-term, sustained earnings growth by leveraging its proven
clinical development capabilities and efficient commercial
execution. For more information, visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.